Peptide
A4 Amyloid Beta
SaveA fragment of amyloid precursor protein central to Alzheimer's disease research, studied as both a biomarker and an immunotherapy target.
Quick verdict
Not a therapeutic peptide itself; anti-amyloid strategies targeting it have yielded mixed clinical results with significant adverse-event profiles.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Vast basic-science literature. Clinical anti-amyloid antibodies show modest efficacy. Direct peptide use is not a recognized therapy.
Benefits
- Central target in Alzheimer's immunotherapy research
- Biomarker utility in neurodegeneration diagnostics
Dosage notes
Not applicable as a standalone therapeutic peptide.
Side effects
- Not administered directly as a therapeutic
- Anti-amyloid therapies carry ARIA risk
Who should be cautious
Not used directly as a therapeutic. Anti-amyloid immunotherapies carry risk of amyloid-related imaging abnormalities (ARIA).
What this page cannot tell you
The amyloid hypothesis remains debated. No standalone peptide therapeutic exists for consumer use.
Leaderboard scores
- Memory15
- Longevity15
Write a review
Sign in to write a review.